Oesophageal Cancer
Oesophageal and OGJ cancer, all histologies
DefinitionClick to collapse
Esophageal and esophagogastric junction (EGJ) cancers are malignant neoplasms arising from the mucosa of the esophagus, a muscular tube derived from the foregut that extends from the cricopharyngeus (approximately 15 cm from the incisors) to the gastroesophageal junction. The primary histologic types are squamous cell carcinoma (SCC) and adenocarcinoma, which differ in etiology, pathology, tumor location, prognosis, and treatment approach [9]. SCC typically arises in the upper and middle thoracic esophagus, often associated with direct carcinogen exposure from tobacco and alcohol. Adenocarcinoma most commonly occurs in the distal esophagus and EGJ, frequently in the setting of Barrett esophagus (BE), a metaplastic condition where the normal squamous epithelium is replaced by columnar epithelium predisposed to malignancy [21]. The 8th edition of the AJCC staging manual defines tumors with epicenter β€2 cm into the proximal stomach as esophageal carcinomas, creating a unified framework for EGJ cancers [10]. Cervical esophageal tumors (<5 cm from the cricopharyngeus) are managed as a distinct entity with definitive chemoradiation [ESOPH-C 1 of 3]. Clinical staging incorporates endoscopic resection (ER) for early tumors, endoscopic ultrasound (EUS), CT, and FDG-PET/CT to determine resectability and guide multidisciplinary management [ESOPH-1].
EpidemiologyClick to collapse
SubtypesClick to collapse
Squamous Cell Carcinoma (SCC)
Malignancy arising from the squamous epithelium of the esophagus, most commonly localized at or above the tracheal bifurcation. Has a proclivity for earlier lymphatic spread and is associated with a poorer prognosis compared to adenocarcinoma [9,10].
Adenocarcinoma
Malignancy arising from columnar or glandular epithelium, most often in the distal esophagus and EGJ. The incidence has risen sharply in North America and Western Europe, reflecting increasing rates of obesity [1].
Mixed Adenosquamous Carcinoma and Other Rare Subtypes
Includes tumors with both squamous and glandular differentiation, as well as carcinomas not otherwise classified. These are staged using the TNM system for SCC [ESOPH-B 1 of 7].
Molecular PathogenesisClick to collapse
Esophageal carcinogenesis involves the accumulation of genetic aberrations, including overexpression of growth factors/receptors, alterations in DNA damage response, and loss of genomic stability [Discussion MS-9]. In SCC, common alterations include TP53 mutations, copy number gains in CCND1 and EGFR, and frequent loss of heterozygosity at multiple loci; the disease is molecularly distinct from adenocarcinoma [Discussion MS-2]. For adenocarcinoma, the molecular landscape shows recurrent amplifications of ERBB2 (HER2) in 15β30% of cases, ERBB2 amplifications are more frequent in EGJ than gastric tumors [150-157]. HER2 positivity is assessed by IHC (scores 0β3+) with confirmatory FISH/ISH for equivocal cases [ESOPH-B 3 of 7]. Microsatellite instability (MSI) due to mismatch repair deficiency (dMMR) occurs in a subset of gastroesophageal adenocarcinomas and is tested universally by PCR, NGS, or IHC [ESOPH-B 5 of 7]. PD-L1 expression measured by combined positive score (CPS) or tumor area positivity (TAP) is used to identify patients likely to benefit from immune checkpoint inhibitors [ESOPH-B 5 of 7]. Rare targetable fusions include NTRK1/2/3 (TRK), RET gene fusions, and BRAF V600E mutations [ESOPH-B 6 of 7]. CLDN18.2 expression, assessed by IHC (β₯75% viable tumor cells with moderate-to-strong staining), defines a subset of adenocarcinomas amenable to zolbetuximab therapy [ESOPH-B 4 of 7]. The molecular heterogeneity underscores the need for comprehensive biomarker testing (IHC/ISH/targeted PCR followed by NGS) to guide targeted therapy [ESOPH-B 6 of 7].
Risk FactorsClick to collapse
Tobacco smoking
Major risk factor for SCC; moderate risk factor for adenocarcinoma. Risk for SCC decreases substantially after cessation, but adenocarcinoma risk remains elevated for years [11-15].
Alcohol consumption
Strongly associated with SCC, acts synergistically with tobacco. Not a major risk factor for adenocarcinoma [11,13].
Obesity (high BMI)
Established as the strongest risk factor for adenocarcinoma, contributes to GERD and Barrett esophagus [12,16,17].
Gastroesophageal reflux disease (GERD)
Major underlying cause of esophageal adenocarcinoma through development of Barrett esophagus [18-20].
Barrett esophagus
Metaplastic columnar epithelium; confers a 30- to 60-fold increased risk of adenocarcinoma [19,21].
Age β₯50 years
Risk increases markedly after age 50 for both histologies, particularly for adenocarcinoma [22-24,75].
Male sex
Males have higher incidence of both SCC and adenocarcinoma; male sex is an independent risk factor for BE and adenocarcinoma [22-24,75].
White race / Non-Hispanic white
Adenocarcinoma is more common in non-Hispanic whites; SCC is more common in African Americans and certain Asian populations [7,8].
Hereditary syndromes
Tylosis (RHBDF2 mutations) β SCC; Fanconi anemia, Bloom syndrome β SCC; Familial Barrett esophagus β adenocarcinoma [26-28,31-33,40,43,44].
Personal history of head and neck cancer
Increases risk for SCC of the esophagus, likely due to shared exposure to tobacco/alcohol [ESOPH-A 1 of 8].
Achalasia, previous esophageal caustic injury
Chronic irritation of the esophageal mucosa increases risk for SCC [ESOPH-A 1 of 8].
Clinical FeaturesClick to collapse
Typical Presentation
The classic presentation of esophageal or esophagogastric junction (EGJ) cancer is dominated by progressive dysphagia, often first noticed with solid foods and later progressing to liquids. Dysphagia is the most common symptom, occurring in most patients at diagnosis [ESOPH-H 1 of 3]. Patients frequently report unintentional weight loss, which may be substantial, as well as odynophagia (painful swallowing). Symptoms of gastroesophageal reflux disease (GERD) are common in patients with adenocarcinoma, particularly those with underlying Barrett esophagus [MS-7]. Other presenting features include nausea, vomiting, and regurgitation. Up to 50% of patients have locoregional disease at diagnosis, while nearly 50% have cancer that extends beyond locoregional confines [MS-7]. The global incidence varies 60-fold between high- and low-incidence regions, with squamous cell carcinoma (SCC) more common in Eastern Europe and Asia, and adenocarcinoma more common in North America and Western Europe [MS-2].
Symptoms
Dysphagia
Progressive difficulty swallowing, initially with solid foods then liquids. Graded on a 0β4 scale: 0 = able to eat solid food normally; 1 = able to swallow food cut into small pieces; 2 = able to swallow semisolid food; 3 = able to swallow liquids only; 4 = unable to swallow liquids or saliva [ESOPH-H 1 of 3].
Weight loss
Unintentional weight loss, often significant, due to decreased oral intake and catabolic effects of malignancy.
Odynophagia
Pain on swallowing, often described as a burning or sharp sensation.
GERD symptoms
Heartburn, regurgitation, and acid reflux are frequent, especially in patients with Barrett esophagus.
Nausea and vomiting
May be due to luminal obstruction or tumor-related dysmotility.
Hematemesis or melena
Bleeding from tumor surface, which can be chronic (iron deficiency anemia) or acute (pre-terminal aorto-esophageal fistula).
Signs
Weight loss and cachexia
Physical wasting, loss of muscle mass, and subcutaneous fat.
Pallor and signs of anemia
Pale conjunctivae, fatigue, and weakness due to chronic blood loss or poor nutrition.
Palpable lymphadenopathy
Supraclavicular (Virchow node) or cervical lymph nodes may be palpable in advanced disease.
Abdominal mass or hepatomegaly
Palpable mass in epigastrium or right upper quadrant if liver metastases are present.
Red FlagsClick to collapse
Progressive dysphagia from solids to liquids (Grade 3 or 4 dysphagia) [ESOPH-H 1 of 3].
Unintentional weight loss >10% of body weight within 3 months.
Odynophagia, especially if severe or persistent.
Acute gastrointestinal bleeding (hematemesis or melena) β may be pre-terminal if associated with aorto-esophageal fistula [ESOPH-H 3 of 3].
New hoarseness or cough β may indicate recurrent laryngeal nerve or tracheal invasion (cT4b disease) [ESOPH-C 1 of 3].
Severe uncontrolled pain after esophageal stent placement β requires immediate endoscopic removal [ESOPH-H 2 of 3].
Complete esophageal obstruction (Grade 4 dysphagia) β requires urgent endoscopic lumen restoration or enteral access [ESOPH-H 2 of 3].
New onset of cough after swallowing (suggests tracheoesophageal fistula) β emergency evaluation needed [ESOPH-C 1 of 3].
InvestigationsClick to collapse
Diagnostic
Esophagogastroduodenoscopy (EGD) with biopsy
Gold standard for diagnosis. Allows direct visualization of tumor, documentation of location, size, circumferential involvement, and degree of obstruction. At least 6β8 biopsies using standard forceps are needed for histologic and molecular interpretation [ESOPH-A 1 of 8].
Endoscopic ultrasound (EUS)
Essential for locoregional staging. Determines depth of tumor invasion (T stage) and identifies regional lymph nodes (N stage). Accuracy is improved with fine-needle aspiration (FNA) of suspicious nodes [ESOPH-A 4 of 8].
Endoscopic resection (ER) of early cancers
Provides precise histologic assessment of depth of invasion for Tis, T1a, and selected T1b tumors (β€2 cm). May be therapeutic if complete excision is achieved [ESOPH-A 5 of 8].
Staging
Chest/abdomen CT with oral and IV contrast
Assesses location and extent of primary tumor, proximity to mediastinal structures, and detection of distant metastases (M stage). Pelvic CT is added if clinically indicated [ESOPH-1].
FDG-PET/CT (skull base to mid-thigh)
Superior to CT alone for detecting distant metastases (M1). Improves detection of occult metastatic disease and helps select patients for curative resection. Limited role in T staging [MS-5].
Bronchoscopy
Required if tumor is at or above the carina to assess for tracheal or bronchial invasion (cT4b). Includes biopsy of any abnormalities and cytology of washings [ESOPH-1].
Laparoscopy with peritoneal washings
Detects radiographically occult peritoneal metastases (M1). Positive cytology defines M1 disease and indicates poor prognosis [ESOPH-C 1 of 3].
Biopsy of metastatic disease
Confirms diagnosis and allows biomarker testing.
Biomarkers
Microsatellite instability (MSI)/mismatch repair (MMR) testing
Universal testing recommended for all newly diagnosed patients. MSI-H/dMMR status guides immunotherapy (pembrolizumab, dostarlimab, nivolumab) [ESOPH-B 5 of 7].
PD-L1 testing (IHC)
Universal testing recommended for all newly diagnosed patients to determine eligibility for PD-1/PD-L1 inhibitors (pembrolizumab, nivolumab, tislelizumab). CPS and TAP scores are interchangeable [ESOPH-B 5 of 7].
HER2 (ERBB2) testing
Recommended for advanced/metastatic adenocarcinoma to select trastuzumab-based therapy. IHC first, followed by ISH if 2+ [ESOPH-B 3 of 7].
CLDN18.2 testing
For advanced/metastatic adenocarcinoma to select zolbetuximab therapy. Positivity if β₯75% viable tumor cells have moderate to strong (2+/3+) membranous staining [ESOPH-B 4 of 7].
Next-generation sequencing (NGS)
Detects ERBB2 amplification, MSI, TMB, NTRK fusions, RET fusions, BRAF V600E. Consider for comprehensive profiling when tissue is limited [ESOPH-B 6 of 7].
Circulating tumor DNA (ctDNA) testing
May identify targetable alterations when tissue is insufficient or for monitoring disease progression. Negative result does not exclude tumor [ESOPH-B 6 of 7].
StagingClick to collapse
AJCC 8th edition, TNM system for carcinoma of the esophagus and esophagogastric junction (effective 2017) [ST-1].
T Categories
| Stage | Description |
|---|---|
| TX | Primary tumor cannot be assessed |
| T0 | No evidence of primary tumor |
| Tis | High-grade dysplasia (HGD) / carcinoma in situ β neoplastic cells confined to epithelium by basement membrane |
| T1 | Tumor invades lamina propria, muscularis mucosae, or submucosa |
| T1a | Tumor invades lamina propria or muscularis mucosae |
| T1b | Tumor invades submucosa |
| T2 | Tumor invades muscularis propria |
| T3 | Tumor invades adventitia |
| T4 | Tumor invades adjacent structures |
| T4a | Tumor invades pleura, pericardium, azygos vein, diaphragm, or peritoneum |
| T4b | Tumor invades other adjacent structures (e.g., aorta, vertebral body, airway) |
N Categories
| Stage | Description |
|---|---|
| NX | Regional lymph nodes cannot be assessed |
| N0 | No regional lymph node metastasis |
| N1 | Metastasis in 1β2 regional lymph nodes |
| N2 | Metastasis in 3β6 regional lymph nodes |
| N3 | Metastasis in β₯7 regional lymph nodes |
M Categories
| Stage | Description |
|---|---|
| M0 | No distant metastasis |
| M1 | Distant metastasis |
Stage Groupings
| Group | Criteria | Clinical Meaning | Five Yr Survival | Treatment Intent |
|---|---|---|---|---|
| SCC β Clinical Stage 0 | cTis N0 M0 | Locoregional disease limited to epithelium | None | Curative β endoscopic therapy preferred |
| SCC β Clinical Stage I | cT1 N0-1 M0 | Locoregional disease invading lamina propria/submucosa with up to 2 positive nodes | None | Curative β endoscopic therapy or esophagectomy |
| SCC β Clinical Stage II | cT2 N0-1 M0 or cT3 N0 M0 | Locoregional disease involving muscularis propria or adventitia, node-negative or up to 2 positive nodes | None | Curative β chemoradiation or esophagectomy |
| SCC β Clinical Stage III | cT3 N1 M0 or cT1-3 N2 M0 | Locoregional disease with adventitial invasion and 1-6 positive nodes | None | Curative intent β chemoradiation Β± surgery |
| SCC β Clinical Stage IVA | cT4 N0-2 M0 or Any T N3 M0 | Locally advanced unresectable (cT4b) or bulky nodal disease (N3) | None | Definitive chemoradiation or palliative |
| SCC β Clinical Stage IVB | Any T Any N M1 | Metastatic disease | None | Palliative systemic therapy and best supportive care |
| Adenocarcinoma β Clinical Stage 0 | cTis N0 M0 | Locoregional disease limited to epithelium | None | Curative β endoscopic therapy preferred |
| Adenocarcinoma β Clinical Stage I | cT1 N0 M0 | Locoregional disease invading lamina propria/submucosa, node-negative | None | Curative β endoscopic therapy or esophagectomy |
| Adenocarcinoma β Clinical Stage IIA | cT1 N1 M0 | T1 with 1-2 positive nodes | None | Curative β esophagectomy Β± neoadjuvant therapy |
| Adenocarcinoma β Clinical Stage IIB | cT2 N0 M0 | Tumor invades muscularis propria, node-negative | None | Curative β esophagectomy Β± neoadjuvant therapy |
| Adenocarcinoma β Clinical Stage III | cT2 N1 M0, cT3 N0-1 M0, cT4a N0-1 M0 | Locoregional disease with variable T and N involvement, up to T4a | None | Curative intent β neoadjuvant therapy + surgery |
| Adenocarcinoma β Clinical Stage IVA | cT1-4a N2 M0, cT4b N0-2 M0, Any T N3 M0 | Locally advanced unresectable (cT4b) or bulky nodal disease | None | Definitive chemoradiation or palliative |
| Adenocarcinoma β Clinical Stage IVB | Any T Any N M1 | Metastatic disease | None | Palliative systemic therapy and best supportive care |
Staging Pearls
- Clinical staging (cTNM) is used for newly diagnosed, untreated patients; pathologic staging (pTNM) for resection without prior therapy; postneoadjuvant staging (ypTNM) for those receiving preoperative therapy [MS-5].
- For SCC, location (upper/middle/lower) and histologic grade (G1βG3) are incorporated into pathologic stage groups but not into clinical stage groups [ST-2].
- For adenocarcinoma, only histologic grade is used in pathologic staging; location does not affect stage [ST-3].
- EGJ tumors with epicenter β€2 cm into proximal stomach are staged as esophageal adenocarcinomas; those >2 cm into stomach are staged as gastric carcinomas [MS-5].
- Celiac nodal involvement in EGJ/distal esophageal cancers may still be considered for combined modality therapy [ESOPH-1A].
- At least 16 regional lymph nodes should be removed and pathologically examined for curative-intent esophagectomy; >30 nodes is desirable [ESOPH-B 2 of 7, ESOPH-C 2 of 3].
- Survival decreases with increasing pT, pN, pM, histologic grade, and age. Survival is better for adenocarcinoma than SCC in the same stage [MS-5].
Management PrinciplesClick to collapse
The management of esophageal and esophagogastric junction (EGJ) cancers requires a multidisciplinary approach integrating surgical oncology, medical oncology, radiation oncology, gastroenterology, radiology, and pathology. Combined modality therapy is supported by category 1 evidence demonstrating efficacy for localized esophagogastric cancer [ESOPH-E]. Treatment philosophy emphasizes individualized care based on histology (squamous cell carcinoma [SCC] vs. adenocarcinoma), stage, performance status, and molecular biomarkers (PD-L1, MSI/MMR, HER2, CLDN18.2). The goal of therapy is curative for locoregional disease and palliative for advanced/metastatic disease. Perioperative systemic therapy (category 1) is preferred for patients with resectable esophageal or EGJ adenocarcinoma who are medically fit, while preoperative chemoradiation is preferred for SCC [ESOPH-F 1 of 12]. Definitive chemoradiation is reserved for unresectable disease or non-surgical candidates. Best supportive care is integral at all stages, especially for palliation [ESOPH-H].
curative
Medically fit, resectable locoregional disease (TisβT4a, N0βN+, M0)
Multimodality therapy: endoscopic therapy (ER Β± ablation) for early-stage (pTis, pT1a, selected pT1b); esophagectomy for T1b or deeper; preoperative chemoradiation (SCC, category 1; adenocarcinoma, category 1 preferred); perioperative chemotherapy (adenocarcinoma, category 1 preferred); definitive chemoradiation for non-surgical candidates or unresectable T4b. Adjuvant nivolumab for residual disease after preoperative chemoradiation (category 1) [ESOPH-F 3 of 12].
palliative
Unresectable locally advanced, recurrent, or metastatic disease
Systemic therapy (first-line and subsequent) based on PS, histology, and biomarkers; palliative radiotherapy; endoscopic stenting for dysphagia; best supportive care. For PS 0β2 (Karnofsky β₯60% or ECOG β€2), systemic therapy with or without palliative/best supportive care. For PS β₯3 (Karnofsky <60% or ECOG β₯3), best supportive care alone [ESOPH-10, ESOPH-21].
definitive non-surgical
Non-surgical candidates (medically unfit or decline surgery) with locoregional disease
Definitive chemoradiation (preferred) for T1bβT4a, any N; endoscopic therapy (ER Β± ablation) for pTis, pT1a, superficial pT1b; palliative RT or best supportive care for those unable to tolerate chemoradiation. For tumors with poor prognostic features (LVI, poor differentiation, positive margins, tumor diameter β₯2 cm), consider definitive chemoradiation [ESOPH-8, ESOPH-19].
The NCCN Panel recommends an infrastructure that encourages multidisciplinary treatment decision-making by all disciplines involved in the care of patients with localized esophagogastric cancer. Frequent meetings (weekly or biweekly) with participation of surgical oncology, medical oncology, gastroenterology, radiation oncology, radiology, and pathology are encouraged. Additional support from nutritional services, social workers, nurses, and palliative care specialists is desirable. Joint review of actual medical data is more effective than reading reports. A brief documentation of consensus recommendations is useful. Re-presentation of select patient outcomes and periodic formal review of relevant literature are encouraged [ESOPH-E].
Performance status (PS) is a key determinant of treatment intensity. The guideline uses Karnofsky Performance Status (KPS) and ECOG PS. For unresectable locally advanced or metastatic disease: KPS β₯60% or ECOG PS β€2 β systemic therapy and/or palliative/best supportive care. KPS <60% or ECOG PS β₯3 β palliative/best supportive care alone [ESOPH-10, ESOPH-21]. Borderline PS patients may be considered for modified or reduced-intensity regimens. In the perioperative setting, patients must be medically fit to tolerate major surgery [ESOPH-2, ESOPH-11]. The FLOT regimen is reserved for those with good PS due to toxicity [ESOPH-F 1 of 12].
Management PathwaysClick to collapse
Branching: Histology (SCC), T-stage (Tis, T1a, superficial T1b), Node status (N0 by ER/imaging), Medical fitness
Branching: Histology (SCC), Clinical T-stage, Nodal status, Risk factors (LVI, size, grade), Medical fitness
Branching: Histology (SCC), T4b (invasion of heart, great vessels, trachea), Medical fitness
Branching: Histology (SCC), T-stage, Nodal status, Ability to tolerate chemoradiation
Branching: Histology (adenocarcinoma), T-stage, Node status, Medical fitness
Branching: Histology (adenocarcinoma), Clinical T-stage, Nodal status, Risk factors (LVI, size, grade), Medical fitness, Biomarkers (MSI/MMR, PD-L1, HER2)
Branching: Histology (adenocarcinoma), T4b (invasion of heart, great vessels, trachea), Medical fitness
Branching: Histology (adenocarcinoma), T-stage, Ability to tolerate chemoradiation
Branching: Histology (adenocarcinoma), Biomarker (MSI-H/dMMR), Resectable locoregional disease
Branching: Histology, PD-L1 CPS, HER2 status, CLDN18.2, MSI/MMR, Performance status, Prior therapy
Pretreatment EvaluationClick to collapse
Clinical Evaluation
Imaging and Endoscopic Staging
Biomarker Testing
Pathologic Assessment
Additional Evaluations
SurgeryClick to collapse
Surgery is a major component of treatment for locoregional esophageal and EGJ cancers, with curative intent for resectable disease. Esophagectomy should be considered for all patients who are physiologically fit with resectable esophageal cancer (>5 cm from cricopharyngeus). Cervical or cervicothoracic cancers <5 cm from cricopharyngeus should be treated with definitive chemoradiation [ESOPH-C 1 of 3]. Surgery also has a role in salvage after definitive chemoradiation for localized recurrence and in carefully selected patients for palliation [ESOPH-C 2 of 3].
Prior to surgery, clinical staging should include CT chest/abdomen, whole-body FDG-PET (integrated FDG-PET/CT preferred), and EUS [ESOPH-C 1 of 3].
All patients should be assessed by an esophageal surgeon for physiologic ability to undergo esophageal resection [ESOPH-C 1 of 3].
Siewert tumor type should be assessed in all EGJ adenocarcinomas. Type I and II are treated per esophageal guidelines; Type III per gastric cancer guidelines [ESOPH-C 1 of 3].
Laparoscopy may be useful for detecting occult metastatic disease, especially for Siewert II/III tumors. Positive peritoneal cytology is M1 disease [ESOPH-C 1 of 3].
Strong consideration should be given to minimally invasive esophagectomy approaches due to improved postoperative outcomes compared to open surgery [ESOPH-C 2 of 3].
In patients unable to swallow during induction therapy, esophageal dilatation or feeding jejunostomy tube (J-tube) is preferred over gastrostomy, which may compromise gastric conduit [ESOPH-C 2 of 3].
Enteral nutritional support via jejunostomy feeding tube is preferred for preoperative nutritional support [ESOPH-C 2 of 3].
A thorough lymph node dissection should be performed. For patients without induction chemoradiation, at least 16 lymph nodes should be removed and assessed. Optimum number after preoperative chemoradiation is unknown, but similar lymph node resection is recommended [ESOPH-C 2 of 3].
Patients with potentially resectable esophageal cancer should undergo multidisciplinary review. Surgery should be performed in high-volume centers by experienced surgeons [ESOPH-C 2 of 3].
Procedures
Ivor Lewis esophagogastrectomy
Distal esophageal and EGJ tumors; most commonly used transthoracic approach [ESOPH-C 2 of 3]
McKeown esophagogastrectomy
Tumors in upper, middle, and lower thoracic esophagus; allows more proximal margin [ESOPH-C 2 of 3]
Transhiatal esophagogastrectomy
Distal esophageal and EGJ tumors; not recommended as routine approach due to lower lymph node retrieval [ESOPH-C 2 of 3]
Minimally invasive esophagectomy (MIE)
Resectable esophageal or EGJ cancer; preferred over open when feasible [ESOPH-C 2 of 3]
Left transthoracic or thoracoabdominal esophagectomy
Distal esophageal and bulky EGJ tumors [ESOPH-C 2 of 3]
Radiation TherapyClick to collapse
Radiation therapy (RT) is integral to the management of esophageal and EGJ cancers, used in preoperative (neoadjuvant), definitive, postoperative (adjuvant), and palliative settings. Treatment recommendations should be made after multidisciplinary consultation using all available diagnostic information (CT, barium swallow, EUS, endoscopy, FDG-PET/CT) [ESOPH-G 1 of 5]. Siewert I/II tumors managed with RT for esophageal cancer; Siewert III managed per gastric cancer guidelines [ESOPH-G 1 of 5].
Principles
- CT simulation and conformal treatment planning should be used with 3D-CRT or IMRT. Proton beam therapy is appropriate when dose reduction to organs at risk (heart, lungs) is needed, ideally within a clinical trial or registry [ESOPH-G 1 of 5].
- Treat patients in supine position for reproducibility [ESOPH-G 1 of 5].
- Use immobilization device. For distal esophageal/EGJ lesions, consider 4D-CT planning for respiratory motion management [ESOPH-G 1 of 5].
- Target volume: GTV includes primary tumor and involved regional lymph nodes; CTV includes 3-4 cm superior/inferior expansion along esophagus and 1 cm radial, plus nodal CTV with 0.5-1.5 cm expansion; PTV expansion 0.5-1 cm accounting for respiratory motion [ESOPH-G 2 of 5].
- Elective nodal coverage depends on tumor location: cervical esophagus β supraclavicular and higher echelon cervical nodes if Nβ₯1; proximal third β para-esophageal and supraclavicular; middle third β para-esophageal; distal third/EGJ β para-esophageal, lesser curvature, splenic nodes, celiac axis [ESOPH-G 2 of 5].
- Normal tissue dose limits should be respected (see below). Treatment planning essential to reduce dose to organs at risk; guidelines may be exceeded based on clinical circumstances [ESOPH-G 3 of 5].
- Supportive care: treatment interruptions avoided; patients seen weekly with vital signs, weight, blood counts; prophylactic antiemetics; antacid/PPI/antidiarrheals as needed; enteral nutrition if caloric intake <1500 kcal/day [ESOPH-G 4 of 5].
Dose Frameworks
| Name | Total Dose | Dose Per Fraction | Fractions | Schedule | Indication |
|---|---|---|---|---|---|
| Preoperative RT | 41.4β50.4 Gy | 1.8β2.0 Gy | 23β28 | Once daily, 5 days per week | For patients receiving preoperative chemoradiation for resectable disease [ESOPH-G 4 of 5] |
| Definitive RT | 50β50.4 Gy | 1.8β2.0 Gy | 25β28 | Once daily, 5 days per week | For definitive chemoradiation in nonsurgical candidates or for those who decline surgery; also for patients at risk for not having surgery due to comorbidities [ESOPH-G 4 of 5] |
| Postoperative RT | 45β50.4 Gy | 1.8β2.0 Gy | 25β28 | Once daily, 5 days per week | For patients with R1/R2 resection or node-positive adenocarcinoma after suboptimal surgery [ESOPH-G 4 of 5] |
Approaches
| Name | Dose Fractionation | Concurrent Chemotherapy | Indication | Key Trial | Toxicities |
|---|---|---|---|---|---|
| Preoperative chemoradiation (preferred for SCC; category 1 for both SCC and selected adenocarcinoma) | 41.4β50.4 Gy in 1.8β2.0 Gy fractions | Preferred: paclitaxel/carboplatin (CROSS trial), fluorouracil/oxaliplatin (FOLFOX). Other: fluorouracil/cisplatin (category 1), irinotecan/cisplatin (category 2B), paclitaxel/fluoropyrimidine (category 2B) [ESOPH-F 3 of 12] | Resectable T2βT4a, N0βN+ esophageal or EGJ cancer; preferred for SCC [ESOPH-G] | CROSS trial [167]: median OS 49 months vs. 24 months (surgery alone); HR 0.657; pCR 49% SCC, 23% adenocarcinoma. NEOCRTEC5010 [322] for SCC: median OS 100.1 vs. 66.5 months; HR 0.71. | Esophagitis, fatigue, hematologic (neutropenia, thrombocytopenia), nausea, pneumonitis, cardiotoxicity |
| Definitive chemoradiation | 50β50.4 Gy in 1.8β2.0 Gy fractions | Preferred: paclitaxel/carboplatin, FOLFOX (category 1), fluorouracil/cisplatin (category 1). Other: cisplatin/docetaxel, cisplatin/paclitaxel, irinotecan/cisplatin (category 2B), paclitaxel/fluoropyrimidine (category 2B) [ESOPH-F 3 of 12] | Unresectable T4b, non-surgical candidates, or patients who decline surgery with locoregional disease [ESOPH-G] | RTOG 85-01 [260,335]: chemoradiation vs. RT alone: median OS 14 vs. 9 months; 5-year OS 27% vs. 0%. PRODIGE5/ACCORD17 [298]: FOLFOX vs. fluorouracil/cisplatin: median PFS 9.7 vs. 9.4 months, not statistically different. | Acute: esophagitis, nausea, vomiting, mucositis, hematologic, fatigue. Late: esophageal stricture, cardiac toxicity, lung fibrosis. |
| Postoperative chemoradiation (fluoropyrimidine-based) | 45β50.4 Gy in 1.8β2.0 Gy fractions | Fluorouracil-based (e.g., bolus fluorouracil/leucovorin per INT-0116, but modified doses preferred due to toxicity) [ESOPH-F 3 of 12] | Adenocarcinoma: R1/R2 resection, or node-positive with suboptimal surgery/poor nodal harvest, or understaged at diagnosis [ESOPH-17]. SCC: R1/R2 resection [ESOPH-6]. | INT-0116 [295,296]: median OS 36 vs. 27 months (surgery alone); 3-year OS 50% vs. 41%; 10-year follow-up confirmed benefit. | Hematologic (neutropenia, thrombocytopenia), GI (nausea, vomiting, diarrhea), fatigue, anastomotic stricture, cardiac toxicity |
| Palliative RT | Variable: e.g., 30 Gy in 10 fractions, 20 Gy in 5 fractions; may use short course | Not routinely; may use chemoradiation for symptom control in selected patients (e.g., TROG 03.01 trial [460] for dysphagia) | Palliation of dysphagia, pain, bleeding from advanced/unresectable tumors [ESOPH-H] | TROG 03.01 [460]: chemoradiation vs. RT alone for dysphagia palliation: no significant difference in dysphagia relief (45% vs. 35%, p=0.13), but higher toxicity with chemoradiation. | Esophagitis, fatigue, fibrosis, fistula risk (especially with brachytherapy or high doses) |
Systemic TherapyClick to collapse
Systemic therapy is used in several settings: perioperative (neoadjuvant/adjuvant) for resectable disease, as part of definitive chemoradiation, and as palliative treatment for advanced/metastatic disease. Regimens recommended for advanced esophageal adenocarcinoma, EGJ adenocarcinoma, and gastric adenocarcinoma may be used interchangeably except as indicated. Selection is based on performance status, comorbidities, toxicity profile, histology (SCC vs. adenocarcinoma), and biomarkers (HER2, PD-L1, MSI/MMR, CLDN18.2, NTRK, BRAF, RET). Oxaliplatin is preferred over cisplatin due to lower toxicity. Two-drug cytotoxic regimens are preferred for advanced disease; three-drug regimens reserved for medically fit patients with good PS. Trastuzumab is added to first-line chemotherapy for HER2-positive adenocarcinoma (IHC 3+ or IHC 2+/ISH+). Checkpoint inhibitors should be added to first-line chemotherapy for patients with PD-L1 CPS β₯1. CPS and TAP scores are highly concordant and may be interchangeable [ESOPH-F 1 of 12]. An FDA-approved biosimilar is appropriate for any recommended biologic therapy. Subcutaneous formulations of pembrolizumab (berahyaluronidase alfa-pmph) and nivolumab (hyaluronidase-nvhy) may be substituted for IV with different dosing instructions [ESOPH-F 1 of 12].
Key Regimens
Treatment Response AssessmentClick to collapse
Title
Response Assessment After Preoperative or Definitive Therapy
Timing
Assessment should be performed β₯5 to 8 weeks after completion of preoperative therapy and prior to surgery. For definitive chemoradiation, assessment endoscopy with biopsy may be deferred to 6 or more weeks after completion [ESOPH-A 6 of 8]. For patients undergoing non-operative management (e.g., immunotherapy), surveillance imaging and EGD should be every 12 weeks for 2 years, then every 6 months until year 5 [ESOPH-A 6 of 8, ESOPH-13A].
Response Logic
-
After preoperative chemoradiation: FDG-PET/CT and chest/abdomen CT with contrast (not required if FDG-PET/CT done) are recommended. EGD with biopsy is optional if surgery is planned, but recommended if surgery is not being considered [ESOPH-5, ESOPH-14, ESOPH-15]. In SCC: if no evidence of disease β esophagectomy or observation (category 2B); if persistent local disease β esophagectomy (preferred) or palliative management; if unresectable/metastatic β palliative management [ESOPH-5]. In adenocarcinoma (post preoperative chemoradiation): same logic; observation category 2B for no evidence of disease [ESOPH-15].
-
After perioperative systemic therapy (adenocarcinoma): FDG-PET/CT and chest/abdomen CT with contrast (not required if FDG-PET/CT done) and EGD with biopsy. If no evidence of disease and patient declines surgery or has unresectable disease β definitive chemoradiation; if medically unfit β definitive chemoradiation or palliative management; if metastatic β palliative management [ESOPH-14].
-
After neoadjuvant immunotherapy for MSI-H/dMMR tumors: FDG-PET/CT, chest/abdomen CT, EGD with biopsy (EUS as clinically indicated). If no evidence of disease β observation or esophagectomy; if persistent local disease β esophagectomy (preferred) or palliative management; if new metastatic β palliative management [ESOPH-16]. Note: current imaging and endoscopic methods do not reliably predict pCR; esophagectomy remains standard outside prospective trials [ESOPH-13A].
-
After definitive chemoradiation: FDG-PET/CT, chest/abdomen CT, and EGD with biopsy. If no evidence of disease β observation (preferred) or esophagectomy; if persistent local disease β esophagectomy (preferred) or palliative management; if new metastatic β palliative management [ESOPH-5, ESOPH-15].
-
Post-treatment FDG-PET results should not be used to select patients for surgery since FDG-PET cannot distinguish microscopic residual disease [ESOPH-5A, MS-11]. FDG-PET is predictive of pathologic response and survival but has limited utility early after therapy due to radiation-induced inflammation [MS-10-11].
Imaging Recommendations
-
FDG-PET/CT (preferred) or FDG-PET scan from skull base to mid-thigh, performed β₯5 to 8 weeks after completion of preoperative therapy [ESOPH-5A, ESOPH-14, ESOPH-15, ESOPH-16].
-
Chest/abdomen CT with oral and IV contrast (not required if FDG-PET/CT is done). Pelvis CT if clinically indicated. CT with contrast should be considered if pre-treatment CT findings merit more accurate anatomic assessment (e.g., small pulmonary nodules) or if post-treatment PET identified new findings [ESOPH-5A, ESOPH-14, ESOPH-15A, ESOPH-16].
-
EGD with biopsy: optional if surgery is planned (to confirm absence of residual disease or provide tissue if non-operative management). Recommended if surgery is not being considered [ESOPH-5A, ESOPH-14, ESOPH-15A].
-
EUS exams after chemotherapy or RT have reduced ability to accurately determine present stage; biopsies may also not accurately diagnose residual disease [ESOPH-A 6 of 8].
-
For non-operative management of adenocarcinoma with MSI-H/dMMR after neoadjuvant ICI: chest/abdomen/pelvis CT (+PET/CT if clinically indicated) and EGD with biopsy (EUS as clinically indicated) every 12 weeks for 2 years, then every 6 months until year 5 [ESOPH-13A, ESOPH-16].
Biopsy Or Salvage Logic
-
Biopsy of suspicious findings on imaging or endoscopy is recommended. Strictures should be biopsied to rule out neoplastic cause. EUS-guided FNA should be performed if suspicious lymph nodes or wall thickening seen on cross-sectional imaging [ESOPH-A 6 of 8].
-
If persistent local disease after preoperative chemoradiation: esophagectomy is preferred for both SCC and adenocarcinoma. For SCC, observation is category 2B if no evidence of disease; for adenocarcinoma, observation is category 2B [ESOPH-5, ESOPH-15].
-
If persistent local disease after definitive chemoradiation: salvage esophagectomy is preferred if resectable and medically fit. Otherwise, palliative management [ESOPH-5, ESOPH-15].
-
If new metastatic disease after any primary treatment: proceed to palliative management (systemic therapy and/or best supportive care) [ESOPH-5, ESOPH-14, ESOPH-15, ESOPH-16].
-
For patients who are nonsurgical candidates and have persistent local disease after definitive chemoradiation, consider palliative RT or best supportive care [ESOPH-8, ESOPH-19].
SurveillanceClick to collapse
Clinical Follow Up Schedule
- For Tis/T1a treated with ER/ablation: EGD every 3 months for year 1, every 6 months for year 2, then annually indefinitely [ESOPH-I Table 1].
- For T1b (N0 on EUS) treated with ER/ablation: EGD every 3 months year 1, every 4-6 months year 2, then annually indefinitely; EUS may be considered with EGD [ESOPH-I Table 1].
- For T1b or greater, any N treated with esophagectomy Β± adjuvant: Imaging (CT chest/abdomen with IV contrast) every 6 months for first 2 years, then annually for up to 5 years; EGD as needed based on symptoms and imaging findings [ESOPH-I Table 1].
- For any T, any N treated with neoadjuvant therapy + esophagectomy: Imaging every 6 months for up to 2 years, then annually for up to 5 years; EGD as clinically indicated [ESOPH-I Table 1].
- For T1bβT4, N0βN+, T4b treated with definitive chemoradiation: Imaging every 3-6 months for first 2 years, then annually for up to 5 years; EGD every 3-6 months for first 2 years, then annually for 3 more years [ESOPH-I Table 1].
- For asymptomatic patients after curative therapy: H&P every 3-6 months for 1-2 years, then every 6-12 months for 3-5 years [ESOPH-9, ESOPH-20].
Imaging Strategy
- CT chest/abdomen with oral and IV contrast (unless contraindicated) is preferred for surveillance imaging [ESOPH-I].
- Alternative imaging: PET/CT or MRI as clinically indicated if patient cannot undergo CT [ESOPH-I footnote b].
- FDG-PET/CT is useful for response assessment after chemoradiation (β₯5-8 weeks after completion) but not for routine surveillance in all settings [ESOPH-5A, ESOPH-14, ESOPH-15].
- CT with contrast should be considered if pre-treatment CT findings merit more accurate anatomic assessment (e.g., small pulmonary nodules) or if post-treatment PET identifies new findings [dd, ESOPH-5A, ESOPH-15A].
- Pelvis CT with contrast as clinically indicated for distal lesions [cc].
- No imaging surveillance is recommended for Tis or T1a tumors after endoscopic therapy [ESOPH-I Table 1].
Laboratory Monitoring
- Chemistry profile and CBC as clinically indicated during follow-up [ESOPH-9, ESOPH-20].
- Monitor vitamin B12, folic acid, vitamin D, and calcium levels in post-esophagectomy patients due to risk of deficiencies [ESOPH-J].
- Monitor blood glucose and blood pressure after esophagectomy as weight loss may improve hypertension and hyperglycemia [ESOPH-J].
- No routine tumor marker surveillance is recommended.
Supportive Follow Up
- Nutritional assessment and counseling at regular intervals [ESOPH-9, ESOPH-20].
- Dilatation of anastomotic or treatment-induced strictures as needed [ESOPH-9, ESOPH-20].
- Smoking cessation advice and resources [ESOPH-1].
- Assess for distress using NCCN Distress Thermometer [ESOPH-1].
- Counsel on healthy lifestyle: maintain healthy weight, physical activity, healthy diet, limit alcohol, smoking cessation [ESOPH-J].
- Coordinate with PCP for routine health maintenance and cancer screening (breast, colorectal, prostate, lung for average-risk survivors) [ESOPH-J].
ComplicationsClick to collapse
Disease-Related
| Complication | Management |
|---|---|
| Dysphagia | Assess severity with standardized scale (Grade 0-4) [454]. For non-curative patients, consider esophageal stent placement (self-expanding metal stents), but avoid in surgical candidates or during chemoradiation due to risk of adverse events [9,10,11]. External beam radiotherapy (EBRT), brachytherapy, photodynamic therapy, and chemotherapy are also options [1,15]. Wire-guided dilation or balloon dilation for severe obstruction, with caution for perforation [7]. |
| Obstruction (complete or severe) | Endoscopic lumen restoration (retrograde/antegrade). If not feasible, establish enteral access (J-tube or gastrostomy). EBRT, brachytherapy (if lumen restored), PDT, chemotherapy. Surgery in select cases. For severe obstruction (liquids only): stent placement (partially or fully covered), EBRT, brachytherapy [1,15]. |
| Bleeding (acute or chronic) | Acute bleeding may be from aorto-esophageal fistula β endoscopic intervention risky, may lead to exsanguination. Tumor surface bleeding: endoscopic electrocoagulation (bipolar, argon plasma) β may initially control but recurrence rate is high [16]. Chronic blood loss: EBRT [16]. |
| Nausea and vomiting | Treat per NCCN Antiemesis guidelines. Evaluate for luminal obstruction; if present, consider endoscopic or fluoroscopic luminal enhancement. |
| Pain | Assess and treat tumor-related pain per NCCN Adult Cancer Pain guidelines. Severe uncontrolled pain after stent placement: consider endoscopic stent removal. |
| Esophageal perforation | Risk increased with dilation of malignant strictures; use wire-guided techniques and avoid overdilation. Management is supportive and may require surgical intervention. |
| Fistula (esophago-respiratory) | Stent placement may be used, but with caution. Large-diameter stents may increase risk of bleeding and fistula [13]. |
Supportive CareClick to collapse
Best supportive care is essential from diagnosis through all stages, regardless of curative or palliative intent. The goal is to prevent and relieve suffering and support the best possible quality of life. A multimodality interdisciplinary approach is encouraged, including surgical oncology, medical oncology, gastroenterology, radiation oncology, radiology, pathology, nutrition services, social workers, nurses, and palliative care specialists [ESOPH-H, ESOPH-E]. For patients with advanced disease, palliative/best supportive care may be combined with systemic therapy depending on performance status.
Nutritional assessment and counseling are recommended for all patients at diagnosis [ESOPH-1]. Enteral feeding tubes (preferably jejunostomy) should be considered for preoperative nutritional support in patients with significant dysphagia or weight loss. Percutaneous gastrostomy may be used for cervical esophageal tumors receiving definitive chemoradiation or marginally resectable disease, but must be discussed with surgeon prior to placement to avoid compromising gastric conduit [ESOPH-2, ESOPH-11]. During chemoradiation, if caloric intake <1500 kcal/day, oral and/or enteral nutrition should be considered [ESOPH-G 4]. Feeding jejunostomy or nasogastric tubes may be placed as needed. For palliative dysphagia, enteral access (J-tube or gastrostomy) is indicated if endoscopic luminal restoration is not possible [ESOPH-H]. In survivorship, monitor weight regularly, especially in first 6 months; monitor vitamin B12, folic acid, vitamin D, calcium levels; refer to dietician for individualized counseling [ESOPH-J]. Encourage small frequent meals for delayed gastric emptying and dumping syndrome.
Prophylactic antiemetics should be given when appropriate during radiation therapy and chemotherapy [ESOPH-G 4]. For nausea/vomiting, treatment should follow NCCN Guidelines for Antiemesis [ESOPH-H]. Nausea and vomiting may also be due to luminal obstruction, so endoscopic/fluoroscopic evaluation is warranted [ESOPH-H]. Specific antiemetic regimens (e.g., 5-HT3 antagonists, NK1 antagonists) are not detailed in this guideline but are referenced to the separate NCCN Antiemesis guideline.
The guideline does not explicitly discuss G-CSF prophylaxis or management. It notes that two-drug cytotoxic regimens are preferred for lower toxicity and that FLOT has significant myelosuppression but no specific G-CSF recommendations. For febrile neutropenia prevention, clinicians should refer to the NCCN Guidelines for Myeloid Growth Factors, which are not reproduced here.
VTE prophylaxis is not specifically addressed in the extracted guideline sections. The panel recommends standard oncologic VTE risk assessment and prophylaxis per institutional practice.
Tumor-related pain should be assessed and treated in accordance with the NCCN Guidelines for Adult Cancer Pain [ESOPH-H]. Severe uncontrolled pain following esophageal stent placement should prompt endoscopic removal of the stent [ESOPH-H]. For chemotherapy-induced neuropathy, duloxetine is recommended for painful neuropathy (not effective for numbness or tingling) [ESOPH-J].
Assess for distress using the NCCN Distress Thermometer and Problem List, which includes social determinants of health [ESOPH-1, ESOPH-1A]. Social workers, nurses, and other support disciplines are desirable participants in multidisciplinary team meetings [ESOPH-E]. Smoking cessation advice, counseling, and pharmacotherapy are recommended as indicated [ESOPH-1].
Dental care is not specifically addressed in the extracted sections. However, given the use of radiation therapy that may involve the esophagus and the potential for mucositis, basic oral care is implied. No specific dental prophylaxis is mentioned.
PrognosisClick to collapse
The prognosis for esophageal and EGJ cancers is generally poor, with an estimated 5-year survival rate remaining low in the United States (Siegel et al., 2023) [8]. Globally, esophageal cancer is the sixth leading cause of cancer-related deaths, with wide geographic variation in incidence [2,3]. Survival is strongly influenced by histologic type, pathologic stage, and treatment response. In the CROSS trial, preoperative chemoradiation plus surgery yielded a 5-year overall survival (OS) of 47% compared to 34% with surgery alone for resectable disease (T2-3,N0-1,M0) [167,310]. The NEOCRTEC5010 trial in esophageal SCC showed median OS of 100.1 months with preoperative chemoradiation versus 66.5 months with surgery alone [322]. For locally advanced adenocarcinoma, perioperative FLOT chemotherapy achieved median OS of 50 months versus 35 months with ECF [168]. The MAGIC trial established a 5-year OS benefit of ~13% for perioperative chemotherapy over surgery alone (36% vs 23%) [332]. Nivolumab adjuvant therapy after preoperative chemoradiation for residual disease improved median disease-free survival from 11 to 22.4 months (CheckMate 577) [294].
By Stage
| Stage | Five Yr Survival | Context |
|---|---|---|
| Clinical stage I (T1,N0) - SCC or adenocarcinoma | Not explicitly provided in source; treatment with endoscopic therapy or esophagectomy offers high cure rates (low risk of nodal metastases) [20,207]. | Early-stage disease includes pTis, pT1a, and select pT1b. Endoscopic therapy is preferred for low-risk tumors (β€2 cm, well/moderately differentiated, no LVI) with low recurrence risk [20,244,245]. |
| Clinical stage II-III (locoregional) - trimodality therapy (preop chemoradiation + surgery) | CROSS trial: 5-year OS 47% (preop chemoradiation + surgery) vs 34% (surgery alone) [310]. For SCC subgroup, median OS 81.6 vs 21.1 months; for adenocarcinoma subgroup, median OS 43.2 vs 27.1 months [310]. | Preoperative chemoradiation (paclitaxel/carboplatin) followed by esophagectomy is a standard approach for medically fit patients with resectable disease [167,310]. |
| Clinical stage II-III - perioperative chemotherapy (adenocarcinoma) | FLOT regimen: median OS 50 months vs 35 months (ECF); 5-year OS not explicitly stated but hazard ratio 0.77 (95% CI 0.63-0.94) [168]. MAGIC trial: 5-year OS 36% vs 23% with perioperative ECF [332]. | Perioperative chemotherapy is a category 1 option for adenocarcinoma of esophagus or EGJ, particularly FLOT or fluoropyrimidine/oxaliplatin [168,292]. |
| yp stage 0 (pathologic complete response after neoadjuvant therapy) | No specific numbers given; but patients with yp stage 0 have lower relapse rates than those with residual disease. The CheckMate 577 trial showed benefit of adjuvant nivolumab for yp T+ and/or N+ disease [294]. | Pathologic complete response (pCR) after preoperative chemoradiation is associated with improved survival [100-106]. Residual primary tumor is associated with shorter OS [101,107]. |
| Unresectable locally advanced or metastatic disease | Poor; median OS with first-line chemotherapy + immunotherapy is approximately 12-14 months in selected populations (PD-L1 CPS β₯5) [348,349]. ATTRACTION-3: nivolumab second-line for SCC gave median OS 10.9 vs 8.4 months [386]. | Palliative systemic therapy can prolong survival and improve quality of life. Performance status guides treatment intensity. Targeted therapies (HER2, PD-L1, CLDN18.2) are used in biomarker-selected populations [156,348,349]. |
Prognostic Factors
- Histologic type: SCC has worse survival than adenocarcinoma in the AJCC 8th edition dataset [10,47].
- Pathologic stage: depth of invasion (pT), nodal status (pN), and distant metastases (pM) are strongly prognostic [46,47].
- Histologic grade: higher grade (G3-4) associated with worse survival [46].
- Age: advancing age is associated with decreased survival [46].
- Tumor location: more distal location within the esophagus is associated with better survival [46,47].
- Treatment response: pathologic complete response after neoadjuvant therapy is a favorable prognostic factor [100-106].
- Resection margin status: R0 resection is associated with better outcomes; R1/R2 with worse [GG].
- Lymphovascular invasion (LVI) and poor differentiation are poor prognostic features in early-stage disease treated endoscopically [kk, aaa].
- PD-L1 expression, HER2 status, MSI-H/dMMR, and CLDN18.2 expression guide systemic therapy and are prognostic in advanced disease [c].
Follow UpClick to collapse
Post Curative Treatment
Follow-up after curative treatment should be systematic but remains controversial with no high-level evidence for optimal surveillance algorithms [ESOPH-I]. Stage-specific surveillance is based on retrospective data and panel consensus. For patients with pStage 0βI (Tis, T1a, T1b) treated endoscopically, endoscopic surveillance (EGD) is recommended at intervals based on depth of invasion: Tis/T1a: every 3 months year 1, every 6 months year 2, then annually indefinitely [ESOPH-A 6, ESOPH-I Table 1]. T1b (N0 on EUS): EGD every 3 months year 1, every 4-6 months year 2, then annually; imaging (CT chest/abdomen) every 6 months for 2 years then annually to 5 years may be considered [ESOPH-I Table 1]. For stage IIβIII treated with definitive chemoradiation, EGD every 3-6 months for 2 years, then annually for 3 years; imaging every 3-6 months for 2 years, then annually to 5 years [ESOPH-I]. For trimodality therapy (preop chemoradiation + surgery), imaging (CT chest/abdomen) every 6 months for 2 years, then annually to 5 years; EGD as clinically indicated [ESOPH-I]. For esophagectomy alone (Β± adjuvant), imaging every 6 months for 2 years then annually to 5 years; EGD as needed based on symptoms [ESOPH-I]. General follow-up for asymptomatic patients: H&P every 3-6 months for 1-2 years, every 6-12 months for 3-5 years; chemistry and CBC as clinically indicated; imaging and EGD as clinically indicated [ESOPH-9, ESOPH-20]. Nutritional assessment and counseling should continue [ESOPH-9, ESOPH-20].
Surveillance Rationale
The rationale for surveillance is based on the pattern of recurrence: ~90% of relapses occur within the first 2 years after completion of local therapy, but potentially actionable relapses can occur >5 years later [ESOPH-I]. Locoregional relapse is common after definitive chemoradiation (especially SCC), making EGD valuable [3]. After trimodality therapy, locoregional relapse is less common, so imaging is preferred. Surveillance beyond 5 years is generally not recommended for esophageal/EGJ-specific cancer, but annual H&P may detect second primary cancers [ESOPH-J]. The goal is to detect early recurrence amenable to salvage therapy, though high-level evidence of survival benefit from intensive surveillance is lacking [ESOPH-I].
Late Effects Screening
- Malnutrition/malabsorption: Monitor weight regularly; progressive weight loss expected first 6 months. Consider monitoring vitamin B12, folic acid, vitamin D, calcium levels. Refer to dietician [ESOPH-J].
- Delayed gastric emptying: Encourage small frequent meals (5/day), minimize high fat/fiber. Refer to gastroenterology for refractory symptoms; consider botulinum toxin injection of pylorus if emptying procedure not done [ESOPH-J].
- Dumping syndrome: Frequent meals, high protein/fiber, low simple carbohydrates, avoid fluids with meals [ESOPH-J].
- Reflux symptoms: Avoid lying flat after eating, use wedge pillow; consider PPI (though usually biliary reflux) [ESOPH-J].
- Anastomotic stricture: Evaluate for and treat with dilation if symptomatic dysphagia [ESOPH-9, ESOPH-20].
- Radiation-induced cardiotoxicity: Coordinate with PCP for cardiac risk factor management (hypertension, diabetes, lipids). Consider referral to cardiologist as clinically indicated [ESOPH-J].
- Chemotherapy-induced neuropathy: Assess for painful neuropathy; duloxetine for pain (not for numbness/tingling) [ESOPH-J].
- Fatigue: Encourage physical activity, energy conservation; address contributing medical/psychosocial factors [ESOPH-J].
- Second primary cancers: Annual H&P; consider screening for head and neck cancers in SCC patients due to risk of second primary SCC [ESOPH-J].
Recurrence Patterns
For SCC, locoregional recurrence is common after definitive chemoradiation (up to 47% at 5 years in historical series) [260,335]. After trimodality therapy, locoregional recurrence is less common; most recurrences are distant [308,437]. For adenocarcinoma, recurrence patterns depend on stage and treatment. yp stage III patients have higher relapse rates and earlier recurrences compared to yp stage 0 patients. The CROSS trial showed that preoperative chemoradiation reduced locoregional recurrence from 34% to 14% and peritoneal carcinomatosis from 14% to 4% [308]. After perioperative chemotherapy, locoregional and distant recurrences occur. Recurrences within the first 2-3 years are most frequent, but late recurrences (>5 years) are possible. Salvage strategies for locoregional recurrence include esophagectomy (if resectable and medically fit) or chemoradiation/chemotherapy/palliative care [ESOPH-9, ESOPH-20].
Key TrialsClick to collapse
| Acronym | Full Name | Year | N | Intervention | Comparator | Population | Primary Endpoint | Key Result | Secondary Outcomes | Practice Change | Journal |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CROSS | Chemoradiotherapy for Oesophageal Cancer Followed by Surgery Study | 2012 | 366 | Preoperative chemoradiation (paclitaxel 50 mg/m2 and carboplatin AUC2 weekly) + surgery | Surgery alone | Resectable esophageal or EGJ cancer (T2-3,N0-1,M0); 75% adenocarcinoma, 23% SCC | Overall survival (OS) | Median OS 49 months (intervention) vs 24 months (control); HR 0.657 (95% CI 0.495-0.871; p=0.003). R0 resection rate 92% vs 69% (p<0.001). 1-,2-,3-,5-year OS: 82%,67%,58%,47% vs 70%,50%,44%,34% [167,310]. | Locoregional recurrence reduced from 34% to 14% (p<0.001); peritoneal carcinomatosis from 14% to 4% (p<0.001). pCR rate 49% for SCC, 23% for adenocarcinoma [308]. | Established preoperative chemoradiation with paclitaxel/carboplatin as standard of care for resectable esophageal cancer. Category 1 recommendation. | New England Journal of Medicine |
| CheckMate 577 | Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer | 2021 | 794 | Nivolumab 240 mg IV every 2 weeks for 16 weeks, then 480 mg every 4 weeks for up to 1 year | Placebo | Patients with completely resected (R0) esophageal or EGJ cancer with residual pathologic disease after preoperative chemoradiation | Disease-free survival (DFS) | Median DFS 22.4 months (nivolumab) vs 11.0 months (placebo); HR 0.69 (95% CI 0.56-0.85; p<0.001) [294]. | DFS benefit independent of PD-L1 expression. Grade 3-4 adverse events 13% vs 6%. | Established adjuvant nivolumab as standard for patients with residual disease after neoadjuvant chemoradiation and R0 resection. Category 1, preferred. | New England Journal of Medicine |
| CheckMate 649 | First-Line Nivolumab Plus Chemotherapy Versus Chemotherapy Alone for Advanced Gastric, Gastro-Oesophageal Junction, and Oesophageal Adenocarcinoma | 2021 | 1581 | Nivolumab 360 mg every 3 weeks + capecitabine/oxaliplatin or modified FOLFOX | Capecitabine/oxaliplatin or modified FOLFOX alone | Previously untreated, HER2-negative, unresectable advanced or metastatic gastric, EGJ, or esophageal adenocarcinoma | OS and PFS in patients with PD-L1 CPS β₯5 | OS (CPS β₯5): median 14.4 vs 11.1 months; HR 0.71 (p<0.0001). PFS (CPS β₯5): 7.7 vs 6.0 months; HR 0.68 (p<0.0001). Benefit also seen in CPS β₯1 and all randomized [348]. | Grade 3-4 adverse events 59% vs 44%. | Established nivolumab + chemotherapy as first-line standard for advanced gastroesophageal adenocarcinoma with PD-L1 CPS β₯5 (category 1) and as a preferred option for CPS β₯1. | Lancet |
| KEYNOTE-590 | Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone for First-Line Treatment of Advanced Oesophageal Cancer | 2021 | 749 | Pembrolizumab 200 mg every 3 weeks + cisplatin + fluorouracil (or capecitabine+oxaliplatin allowed later?) | Placebo + chemotherapy | Previously untreated, locally advanced or metastatic esophageal cancer (SCC, adenocarcinoma, or EGJ adenocarcinoma) | OS and PFS in patients with SCC and PD-L1 CPS β₯10, SCC, all patients | OS in SCC CPS β₯10: 13.9 vs 8.8 months; HR 0.57 (p<0.0001). OS in SCC: 12.6 vs 9.8 months; HR 0.72 (p=0.0006). OS in all patients: 12.4 vs 9.8 months; HR 0.73 (p<0.0001). PFS in SCC: 6.3 vs 5.8 months; HR 0.65 (p<0.0001) [349]. | Grade 3-5 treatment-related adverse events 72% vs 68%. | Established pembrolizumab + chemotherapy as first-line treatment for esophageal cancer, particularly for SCC and PD-L1 CPS β₯10. Category 1 for combination with cisplatin; preferred option. | Lancet |
| FLOT4 | Perioperative Chemotherapy with Fluorouracil Plus Leucovorin, Oxaliplatin, and Docetaxel Versus Fluorouracil or Capecitabine Plus Cisplatin and Epirubicin for Locally Advanced, Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma | 2019 | 716 (phase III) | Perioperative FLOT (4 cycles pre and 4 cycles post) | Perioperative ECF (3 cycles pre and 3 cycles post) | Resectable gastric or EGJ adenocarcinoma (β₯cT2 and/or N+) | Overall survival (OS) | Median OS 50 months (FLOT) vs 35 months (ECF); HR 0.77 (95% CI 0.63-0.94). pCR rate 16% vs 6% (p=0.02) [168]. | Grade 3-4 adverse events 25% vs 40% (FLOT lower). Serious adverse events 27% in both groups. | FLOT became the preferred perioperative chemotherapy regimen for resectable gastric/EGJ adenocarcinoma, replacing ECF. Category 1 recommendation. | Lancet |
| ToGA | Trastuzumab in Combination With Chemotherapy Versus Chemotherapy Alone for Treatment of HER2-Positive Advanced Gastric or Gastro-Oesophageal Junction Cancer | 2010 | 594 | Trastuzumab + cisplatin + fluorouracil or capecitabine | Cisplatin + fluorouracil or capecitabine | HER2-positive (IHC 3+ or FISH+) advanced gastric or EGJ adenocarcinoma | Overall survival | Median OS 13.8 vs 11.0 months; HR 0.74 (95% CI 0.60-0.91; p=0.046). In IHC 2+/FISH+ or IHC 3+ subgroup: median OS 16.0 vs 11.8 months; HR 0.65 [156]. | ORR 47% vs 35%; grade 3-4 adverse events similar. | Established trastuzumab + chemotherapy as first-line standard for HER2-positive advanced gastroesophageal adenocarcinoma. | Lancet |
| ATTRACTION-3 | Nivolumab Versus Chemotherapy in Patients with Advanced Oesophageal Squamous Cell Carcinoma Refractory or Intolerant to Previous Chemotherapy | 2019 | 419 | Nivolumab 240 mg every 2 weeks | Investigator's choice of docetaxel or paclitaxel | Advanced esophageal SCC refractory or intolerant to at least one prior fluoropyrimidine- and platinum-based regimen | Overall survival | Median OS 10.9 vs 8.4 months; HR 0.77 (95% CI 0.62-0.96; p=0.019). OS benefit observed regardless of PD-L1 expression [386]. | ORR 19.3% vs 21.5%; median duration of response 6.9 vs 3.9 months. Grade 3-4 adverse events 18% vs 63%. | Nivolumab became a category 1 preferred second-line option for advanced esophageal SCC. | Lancet Oncology |
| KEYNOTE-181 | Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer | 2020 | 628 | Pembrolizumab 200 mg every 3 weeks | Investigator's choice of docetaxel, paclitaxel, or irinotecan | Advanced SCC or adenocarcinoma of esophagus/EGJ progressing after first-line therapy | OS in SCC PD-L1 CPS β₯10, SCC, and all patients | OS in SCC CPS β₯10: 9.3 vs 6.7 months; HR 0.69 (95% CI 0.52-0.93; p=0.007). 12-month OS 43% vs 20%. No significant OS benefit in overall population or SCC overall [387, 92]. | Grade 3-5 adverse events 18% vs 41%. | Pembrolizumab became a category 1 preferred second-line option for esophageal SCC with PD-L1 CPS β₯10. | Journal of Clinical Oncology |
| NEOCRTEC5010 | Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus | 2018 | 451 | Preoperative chemoradiation (vinorelbine + cisplatin with RT) + surgery | Surgery alone | Locally advanced esophageal SCC | Overall survival | Median OS 100.1 vs 66.5 months; HR 0.71 (95% CI 0.53-0.96; p=0.025). 5-year OS rates not explicitly given. R0 resection rate 98.4% vs 91.2% (p=0.002). Median DFS 100.1 vs 41.7 months; HR 0.58 (p<0.001) [322]. | Postoperative complications similar between groups. | Strengthened evidence for preoperative chemoradiation in SCC, showing long-term survival benefit over surgery alone. | Journal of Clinical Oncology |
Clinical PearlsClick to collapse
- Pearl 1: Multidisciplinary team management is essential before initiating any therapy for localized esophagogastric cancer. Joint review of staging studies (CT, EUS, PET/CT, endoscopy) by surgical, medical, and radiation oncology, radiology, and pathology optimizes treatment planning [ESOPH-E].
- Pearl 2: Endoscopic resection (ER) is critical for accurate staging of early-stage cancers (Tis, T1a, T1b β€2 cm) because it provides more precise depth of invasion than EUS. ER can be both diagnostic and therapeutic for low-risk tumors (β€2 cm, well-differentiated, no LVI, negative margins) [ESOPH-A].
- Pearl 3: For locally advanced adenocarcinoma of the esophagus or EGJ, perioperative chemotherapy (FLOT or FOLFOX) and preoperative chemoradiation (CROSS regimen) have shown comparable survival in the NEO-AEGIS trial, making both valid options. FLOT is preferred for medically fit patients with good PS; preoperative chemoradiation is preferred for borderline resectable tumors or when FLOT is not feasible [ESOPH-F 1].
- Pearl 4: CheckMate 577 established that adjuvant nivolumab for 1 year improves disease-free survival in patients with residual disease after preoperative chemoradiation and R0 resection, regardless of PD-L1 expression. This is now a category 1, preferred option for yp T+ and/or N+ [294].
- Pearl 5: PD-L1 testing (CPS or TAP score) is recommended for all newly diagnosed patients, and a checkpoint inhibitor should be added to first-line chemotherapy for advanced disease with PD-L1 CPS β₯1. CPS and TAP scores are highly concordant and interchangeable [ESOPH-B 5, ESOPH-F 1].
- Pearl 6: For early-stage SCC (pTis, pT1a), endoscopic therapy is preferred. Ablation of SCC after ER has low evidence, but can be used for multifocal HGD. Ensure all remaining dysplasia is eradicated. For high-risk T1b SCC (β₯200 ΞΌm invasion, LVI, poor differentiation), esophagectomy or chemoradiation is recommended due to risk of nodal metastases [ESOPH-A 2, ESOPH-A 5].
- Pearl 7: Surveillance after definitive chemoradiation for locally advanced disease should include EGD every 3-6 months for 2 years then annually for 3 years, plus imaging every 3-6 months for 2 years then annually to 5 years, because locoregional recurrence is common [ESOPH-I Table 1].
- Pearl 8: Patients with MSI-H/dMMR tumors have high response rates to immune checkpoint inhibitors. For resectable disease, non-operative management is investigational; esophagectomy remains standard outside clinical trials. If non-operative management is chosen, immunotherapy should be continued for at least 1 year with intensive surveillance [ESOPH-13A].
- Pearl 9: In advanced esophageal cancer, two-drug cytotoxic regimens (e.g., FOLFOX or XELOX) are preferred over three-drug regimens due to lower toxicity. Oxaliplatin is preferred over cisplatin. Trastuzumab is added for HER2-positive disease; zolbetuximab for CLDN18.2-positive; checkpoint inhibitors for PD-L1 CPS β₯1 [ESOPH-F].
- Pearl 10: Minimally invasive esophagectomy (MIE) approaches (Ivor Lewis or McKeown) are strongly considered due to improved postoperative outcomes compared to open surgery, including lower pulmonary complications and shorter hospital stay. Robotic-assisted MIE is emerging but requires further study [ESOPH-C 2].
Special SituationsClick to collapse
MSI-H/dMMR resectable adenocarcinoma
HER2-positive advanced/metastatic adenocarcinoma
CLDN18.2-positive advanced/metastatic adenocarcinoma
NTRK gene fusion-positive tumors (adenocarcinoma or SCC)
T4b (unresectable) tumor invading trachea, great vessels, or heart
Cervical esophageal cancer (β€5 cm from cricopharyngeus)
Nonsurgical candidates with early-stage disease (Tis-T1b, N0)
Positive peritoneal cytology without visible implants (M1 disease)
Guidelines ResourcesClick to collapse
NCCN Clinical Practice Guidelines in Oncology: Esophageal and Esophagogastric Junction Cancers
AJCC Cancer Staging Manual, 8th Edition
ASGE guideline on screening and surveillance of Barrett's esophagus
AGA Clinical Practice Update on New Technology and Innovation for Surveillance and Screening in Barrett's Esophagus
Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline
Protocol for the Examination of Specimens from Patients with Carcinoma of the Esophagus
Endoscopic Submucosal Dissection for Superficial Gastrointestinal Lesions Guideline - Update 2022
Protective FactorsClick to collapse
- Smoking cessation: Risk for esophageal SCC decreases substantially after quitting smoking; however, the risk for adenocarcinoma remains unchanged even years after cessation [14,15].
- Weight control and healthy diet: Although not explicitly listed as a protective factor in the source, maintaining a healthy body weight is recommended in survivorship to reduce cancer risk [ESOPH-J 3 of 4].